Pfizer Licenses Cell Line Tech from Lonza and BioWa
Newly rejigged Pfizer has licensed a cell line tech developed by Lonza and BioWa for use in its therapeutic antibody programme.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs